Fate Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview

Fate Therapeutics

03/08/2021 24:00

* Fate Therapeutics Inc  FATE.OQ   FATE.O  is expected to show a
rise in quarterly revenue when it reports results on August 4. 
* The San Diego, California-based company is expected to report 
 a 15.4% increase in revenue to $6.307 million from $5.47
million a year ago, according to the mean estimate from 15
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Fate Therapeutics Inc
is for a loss of 53 cents per share. For the same quarter last
year, the company reported a loss of 35 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 13 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Fate
Therapeutics Inc is $115​, about 26% above​ its last closing
price of $85.08. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.45       -0.43      -0.48     Missed  -10.9
 Dec. 31 2020  -0.40       -0.39      -0.61     Missed  -55.2
 Sep. 30 2020  -0.36       -0.36      -0.68     Missed  -87.5​
 Jun. 30 2020  -0.27       -0.27      -0.35     Missed  -29.6
 Mar.          -0.39​      -0.39      -0.44     Missed  -13.1​
 31​ 2020​                                              
 Dec. 31 2019  -0.41       -0.39      -0.37     Beat    4.1​
 Sep. 30 2019  -0.38       -0.38      -0.40     Missed  -6.2
 Jun. 30 2019  -0.34       -0.33      -0.36     Missed  -10
 This summary was machine generated August 2 at 23:00 GMT.  All
figures in US dollars unless otherwise stated